奥美沙坦酯治疗轻中度原发性高血压的疗效分析

目的探讨奥美沙坦酯治疗轻中度原发性高血压的临床疗效及安全性。方法将我院2010年9月～2012年3月收治的120例轻中度原发性高血压患者按照数字表法分为实验组和对照组，实验组患者采用奥美沙坦酯进行治疗，对照组患者采用氯沙坦钾进行治疗，疗程均为8w。在安慰剂末期及疗程结束时，对两组患者进行24h动态血压监测，比较治疗前后血压、心率、心电图、实验室检查相关指标的变化以及不良反应发生情况。结果治疗2、4、6、8w时，两组平均坐位舒张压（MSDBP）及平均坐位收缩压（MSSBP）水平均较基线水平明显下降（P〈0．01）；治疗8w时，实验组MSDBP及MSSBP水平均明显低于对照组，差异有统计学意义（P〈0．05，P〈0．01）。实验组总有效率略高于对照组，但差异无统计学意义（P〉0．05）；实验组MSDBP和MSSBP个体及总体T／P比值均高于对照组，差异有统计学意义（P〈0．01），且实验组不良反应发生率略低于对照组。结论对于轻中度原发性高血压患者的治疗，奥美沙坦酯在24h内的持续降压作用时间更长，降压幅度优于氯沙坦钾，且不良反应较轻，作用更强。

Effects of OImesartan Medoxomil for Mild and Moderate Primary Hypertension

Objective To investigate the clinical effects and safety of olmesartan medoxomil for treating mild and moderate primary hypertension. Methods 120 patients with mild and moderate primary hypertension in our hospital from September 2010 to March 2012 were randomly divided into experimental group and control group. The patients in experimental group were treated with olmesartan medoxomil for 8 weeks, while those in control group with losartan potassium for 8 weeks. At the end of placebo and course of treatment, 24 h ambulatory blood pressure monitoring （ABPM） was given to the patients in two groups. The changes of blood pressure, heart rate, electrocardiogram and laboratory-related indexes before and after treatment as well as adverse reactions were compared. Results At the time of 2, 4, 6 and 8 week treatment, MSDBP and MSSBP levels in two groups were decreased obviously than the baseline （P〈0.01）. At the time of 8-week treatment, MSDBP and MSSBP levels in experimental group were significantly lower than in control group, and the difference had statistical significance （P 〈0.01）. The total effective rate of experimental group was slightly higher than control group, but there was no significant difference （P〉0.05）. The individual and overall MSDBP and MSSBP T/P ratios in experimental group were higher than in control group, and the difference had statistical significance （P〈0. 01）. In addition, its incidence of adverse reactions was slightly lower than control group. Conclusion For mild and moderate primary hypertension, olmesartan medoxomil has a longer action time for decreasing blood pressure persistently within 24 h, with milder adverse reactions and stronger function, and its range of decreasing blood pressure is superior to losartan potassium.